What EMD Serono's Pricing Agreement Really Means
An 84 percent discount on fertility medications, a new government-branded sales platform, and a pharmaceutical company voluntarily signing on to a program that carries the president's name: on the surface, the deal between EMD Serono and the Trump administration to lower the cost of fertility drugs reads like a clear win for patients. Look closer, though, and a far more complicated picture emerges, one of trade policy, pricing strategy, and the limits of what a drug discount can actually accomplish.
The starting point: an IVF cycle costs more than just medication
In vitro fertilization is among the most expensive routine medical treatments in the United States. A single cycle runs between $15,000 and $30,000, with medications accounting for roughly one-fifth of that total, according to the American Society for Reproductive Medicine (ASRM). In February 2025, President Trump signed an executive order aimed at expanding access to IVF treatment. A central tool for that effort arrived in June 2025 with the FDA's National Priority Voucher program, which offers companies faster review timelines in exchange for concessions on pricing and domestic manufacturing.
EMD Serono, Merck KGaA's North American biopharma arm, was one of the first companies to take up that offer. In October 2025, the company's combination fertility drug Pergoveris received the corresponding priority designation, and CEO Belén Garijo said the company was committed to working with the U.S. administration to create value over the long term. That diplomatic phrasing obscures what the arrangement actually is: a trade of tariff relief and expedited review for publicly visible price concessions.
The mechanism: Most Favored Nation pricing and TrumpRx
At the core of the deal is a so-called Most Favored Nation (MFN) clause. The underlying idea is straightforward: a company cannot charge a higher price in the United States than it charges in comparably wealthy industrialized nations. For three of EMD Serono's central IVF drugs, Gonal-f, Cetrotide, and Ovidrel, that logic was translated into a concrete figure. When all three medications are used together in a typical stimulation cycle, the White House says the arrangement amounts to an 84 percent discount off the previous list price. For Gonal-f alone, some reports cited discounts as steep as 796 percent off the original list price, a figure that illustrates just how far U.S. list prices had drifted from the net prices customary elsewhere before the reform.
The drugs aren't sold through the government itself but through TrumpRx, a platform announced in September 2025 and launched on February 5, 2026, after slipping from its originally planned January debut. TrumpRx is not technically a mail-order pharmacy; it functions as a central directory that routes consumers to manufacturers' own websites. Payment is cash only, with no insurance billing built into the platform. By June 2026, the site's catalog had grown to more than 800 products from a range of manufacturers, from Pfizer to AstraZeneca to Amgen, supplemented by partnerships with Amazon Pharmacy, GoodRx, and Cost Plus Drugs. For lower-income patients under 550 percent of the federal poverty level, additional discounts apply to fertility drugs like Gonal-f.
What the discount actually covers, and what it doesn't
The figure cited by the Centers for Medicare and Medicaid Services (CMS), that patients could save up to $2,200 per cycle, applies exclusively to those three medications. That's precisely the point professional bodies like ASRM raise in their assessment of the program: a complete IVF cycle typically requires additional medications for endometrial preparation, infection prevention, and precise cycle timing that the agreement doesn't touch. More importantly, by far the largest cost components of an IVF cycle, egg retrieval and embryo transfer, fall entirely outside the deal. ASRM concludes that the medication pricing addresses only a narrow slice of the real cost problem and warns that without structural measures, existing disparities in access could persist or even widen. An analysis from the Kaiser Family Foundation (KFF) points out that the program comes with no employer mandate, merely clarifies existing rules around workplace family-building benefits, and leaves the roughly 16 million Medicaid enrollees of reproductive age untouched, since most state Medicaid programs don't cover fertility treatment to begin with.
A more fundamental question concerns how TrumpRx functions in practice. A New York Times analysis found several instances where prices listed on the platform, despite the official discounts, were higher than in other wealthy countries, in some cases double. Critics, including Democratic senators, have described the program less as systemic drug-pricing reform than as a marketing tool with the character of a coupon program. That critique is sharpened by the branding itself: a YouGov survey found that the name "TrumpRx" alone measurably lowered approval among Democratic and independent respondents while boosting it among Republicans, a finding that shows how thoroughly what is ostensibly a health-policy instrument has become a partisan symbol.
The manufacturers' perspective
From the perspective of the participating drugmakers, the deal makes commercial sense despite the highly publicized price cuts. In exchange for the MFN commitments and participation in TrumpRx, EMD Serono secured a tariff exclusion agreement with the U.S. Department of Commerce, tied to commitments on domestic manufacturing and research investment, according to the company its first U.S. manufacturing investment of this kind. Similar dynamics are visible among other participants: Pfizer, for instance, secured relief from threatened 100 percent tariffs as part of its own TrumpRx arrangement. The discounts, in other words, can be read as the price manufacturers pay for regulatory and trade-policy certainty, rather than primarily as a concession on drug affordability.
What it means for pharma communications
For the corporate communications teams at the companies involved, this situation creates a distinctive challenge. A move that is understood internally as a strategic trade-off among tariff policy, expedited approvals, and pricing pressure has to be communicated externally as a contribution to a socially charged issue like fertility treatment, and it has to be communicated within a political environment where the program's own branding carries partisan weight. Between the language of "long-term value creation in partnership with the U.S. administration" and professional societies' criticism of the program's limited real-world impact lies a narrow path that press releases and background materials have to navigate, one that neither raises false expectations among patients nor downplays the company's own cooperation with the administration. It's precisely at this intersection of regulatory precision and political sensitivity that pharmaceutical communications today demands more than product messaging alone.
Sources
- FiercePharma – Merck KGaA's EMD Serono strikes MFN deal in Trump's fertility treatment pricing push
- Endpoints News, Oct 17, 2025 – Trump announces 'most favored nation' deal with EMD Serono to boost IVF access
- EMD Serono, Oct 16, 2025 – Agreement with U.S. Government to Expand Access to IVF Therapies
- KFF – Will Trump's Announcement Expand Access to IVF?
- American Society for Reproductive Medicine – Evaluating the Trump Administration's Initiative on IVF
- American Society for Reproductive Medicine – ASRM Responds to TrumpRx Announcement, Says IVF Access Requires More Than Lower Drug Prices
- AJMC – TrumpRx Launch Brings Savings—and Uncertainty
- Wikipedia – TrumpRx
- Axios, Oct 16, 2025 – Trump announces plan to lower cost of IVF drugs
Adrian Kempf
Pharma Communications Writer, Graphic & Media Designer Kirchzarten im Dreisamtal, Germany
Usage & Citation Permission
Full or partial reproduction of this text is permitted with source attribution. Please cite as: "Adrian Kempf, pharmavisuell"
This text may be forwarded, published, shared on social media, or posted publicly.
Editorial abridgment is permitted as long as the meaning and message of the text are not distorted.
This usage permission applies to the specialist articles published on pharmavisuell.de. Individually commissioned texts are subject to separately agreed usage rights.
© Adrian Kempf, pharmavisuell – Kirchzarten im Dreisamtal
https://pharmavisuell.de